3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis

Three new studies have individually shown the anti-TNF (tumour necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis (JIA), and associated with improved Health-Related Quality of Life (HRQoL) in a substantial proportion of children with JIA.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news164034519.html">3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis</a></p> <p>Three new studies have individually shown the anti-TNF (tumour necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis (JIA), and associated with improved Health-Related Quality of Life (HRQoL) in a substantial proportion of children with JIA. </p>